$ADXS Legit Reasons To Take Another Look at Under Appreciated Cancer Immunotherapy
just the beginning
Zacks. Strong Fourth Quarter and Full Year 2014
CYBR in $70 Billion Market - Worldwide spending on IT security in 2014was about $70 billion.
Cyber Security Market Forecast 2014-2024
LONDON /PRNewswire/ -- With attackers able to strike from anywhere and inflict damage on a significant (but often unnoticed) scale, the threat has never been greater. As a consequence, visigain has assessed that the value of the global Cyber Security market in 2014 will reach $76.68bn and will continue to grow
By Paul M. Barrett -March 11, 2015
Second Sight’s ( EYES ) Argus II Retinal Prosthesis System is the first patented and approved retinal prothesis in the world. " Millions stand to benefit from this life-changing technology. "
Updates on Biotech Stocks Celladon Corporation ( CLDN )Top line data due out on Systolic Heart Faiure.They have FDA Fast Track and Breakthrough Therapy Designations. We think this stock couldsee $80.
Updates on Biotech Stocks Celladon Corporation ( CLDN )Top line data due out on Systolic Heart Faiure.They have FDA Fast Track and Breakthrough Therapy Designations. We think this stock could see $80.
Celladon Shares May Have Upside to $70
The developer of gene therapy for heart failure to announce pivotal trial results.
We are initiating coverage of Celladon with a Buy rating and target of $70.
The total annual cost of treating heart failure today is $39 billion in the U.S. alone. By virtue of investment in Celladon, a number of pharmaceutical companies have a front row seat to evaluate the significance of CUPID 2. We anticipate a licensing or a merger and acquisition (M&A) transaction, if results are promising for future success
Do The DD FOLKS :
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
PRINCETON, N.J., Aug. 25, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck's investigational anti PD-1 antibody, pembrolizumab.
Biotech to see continued growth in 2015: HC Wainwright
by Mourad Haroutunian
Both Advaxis (NASDAQ:ADXS) has benefited from strong interest Marque Investors Adage Capital Management and T. Rowe Price Associates invested nearly $17 million into Advaxis